KM Research Hub
← 返回论文库
待处理 入排:排除 图源:待检查

Fosfomycin versus ciprofloxacin for febrile neutropenia prophylaxis in high-risk haematological patients (FOVOCIP): a phase 3, open-label, multicentre, randomised, non-inferiority trial.

Ahinoa Fernández Moreno, Paula López de Ugarriza, Ana Julia González Huerta, Blanca Boluda Pascual, Sara Cáceres, Laura Solán Blanco, Maria Luisa Calabuig, Marta Polo Zarzuela, Rebeca Rodríguez-Veiga, Pau Montesinos, Ana María Fernández Verdugo, Eva M González-Barbera, María Izquierdo, Marina Medel-Plaza, Javier Colomina, Maria Teresa Olave, Karem Humala, Laura López, Jorge Labrador, Cristina Seral, Maria Luz Amigo, Maria de Toro, Guillermo Ruiz Carrascoso, Gregoria Megías, Rosa Blázquez, María Antuña, Pilar Lumbreras, Javier Fernández Domínguez, Teresa Bernal

Lancet Reg Health Eur 66 101698

PMID42164340
PMCIDPMC13186043
DOI10.1016/j.lanepe.2026.101698
发表日期2026-05-21
摘要

摘要

BACKGROUND: Prophylaxis with fluoroquinolones in high-risk neutropenic patients is currently under scrutiny. The FOVOCIP study aimed to evaluate the efficacy and safety of fosfomycin compared to ciprofloxacin in this population. METHODS: This was a multicentre, randomised, phase-3, non-inferiority, open-label trial performed in 11 centres in Spain. Adults diagnosed with acute leukaemia or recipients of a Haematopoietic Stem Cell Transplant were randomised to receive oral fosfomycin or oral ciprofloxacin as prophylaxis. The primary endpoint was rate of febrile neutropenia. Intention-To-Treat (ITT) and Per-Protocol (PP) analyses were done for the primary endpoint, with a non-inferiority margin of -5%. FINDINGS: A total of 174 patients were screened and 166 randomized (83 per arm, 50% female). In the ITT population, febrile neutropenia occurred in 74.7% (62 of 83 patients) and 73.49% (61 of 83 patients) in the fosfomycin and ciprofloxacin group, respectively. The corresponding success rates (patients without febrile neutropenia) were 25.3% in the fosfomycin group and 26.51% int the ciprofloxacin group, risk difference -1.2%, (95% confidence interval [CI]: -14.5 to 12.12, lower boundary of the 90% CI -12.3). In the PP population, febrile neutropenia occurred in 82.19% (60 of 73 patients) and 76.25% (61 of 80 patients) in the fosfomycin and ciprofloxacin group respectively. The corresponding success rates were 17.81% in the fosfomycin group and 23.75% in the ciprofloxacin group, risk difference -5.94%, (95% CI: -18.75 to 6.86, lower boundary of the 90% CI -16.7). Gram negative bacteria were responsible for 90% and 10% of the bacteraemias in the fosfomycin and ciprofloxacin group, respectively. Two patients (3%) in the experimental group became colonized by multidrug resistant Gram-negative bacteria, compared with nine patients (11%) in the control group (P = 0.04). There were no differences in other safety endpoints. INTERPRETATION: Fosfomycin did not demonstrate non-inferiority to ciprofloxacin in the prevention of febrile neutropenia in high-risk haematological patients. The higher incidence of Gram-negative bacteraemia also discourages its use. This trial is registered with ClinicalTrials.gov (NCT05311254) and EUDRACT (2021-000354-25) and is complete. FUNDING: Instituto de Salud Carlos III (PI21/1590 AES 2021, co-funded by European Union), Agencia SEKUENS (IDE/2024/000797), Instituto de Investigación del Principado de Asturias (ITM25-INT).

KM 提取结果

0 个 Figure · 0 个 KM 面板

尚未提取到 KM 面板。